6-(alkanolaminoaryl)-3(2H)-pyridazinone derivatives, and their use

Abstract

Novel 6-(acylaminoaryl)-3(2H)-pyridazinones of the formula ##STR1## where R 1 , R 2 , R 3 , R 4 , A and B have the meanings given in the description, and their preparation are described.[.and inhibiting thrombocyte aggregation and gastric secretion.].. The compounds are useful for treating disorders .Iadd.and inhibiting thrombocyte aggregation and gastric secretion.Iaddend..

We claim: 
     
       1. A 6-(alkanoylaminoaryl)-3(2H)-pyridazinone derivative of the formula I ##STR552## wherein the substituents on the phenylene radical are para to one another, A and B are each hydrogen or together form a bond, R 1  is hydrogen or methyl, R 2  is hydrogen or, where A and B are each hydrogen R 1  and R 2  together form a C 1  -C 2  -alkylene radical, R 3  is a straight-chain .[.C 1  -C 4  -alkylene.]. .Iadd.C 2  -C 4  -alkylene .Iaddend.group which can be substituted by C 1  -C 3  -alkyl group or by two methyl groups, and R 4  is (b) a group of the formula II ##STR553## where the broken line can be an additional bond, R 5  is C 1  -C 4  -alkyl which is .[.unsubstituted or.]. substituted by phenyl, or phenyl which is unsubstituted or substituted by 1 or 2 halogen atoms, or is a group of the formula R 7  R 8  N, where R 7  is hydrogen or phenyl, and R 8  is C 1  -C 4  -acyl or benzoyl, or R 7  and R 8 , together with the nitrogen atom, form a benzimidazol-2-on-1-yl group, R 6  is C 1  -C 4  -alkyl, hydroxyl, C 1  -C 4  -acyl, (C 1  -C 5  -alkoxy)-carbonyl or cyano, or R 5  and R 6  together form a C 1  -C 4  -alkylene chain, and m is 0, 1 or 2, or   (c) a group of the formula III ##STR554## .[.'.]. where R 9  is a C 1  -C 3  -hydrocarbon radical .[.which may be.]. substituted by phenyl or a C 3  -C 8  -cycloalkyl (in which case a C 5  -C 8  -cycloalkyl group can be benzofused) or C 6  -C 10  -aryl which can contain 1 to 3 C 1  -C 4  -alkyl, C 1  -C 4  -alkoxy, trifluoromethyl, nitro, hydroxyl, C 1  -C 4  -acyl, carboxyl, (C 1  -C 5  -alkoxy)-carbonyl, amido, N-(C 1  -C 4  -alkyl)amido, N,N-di-(C 1  -C 4  -alkyl)amido, tri(C 1  -C 4  -alkyl)-silyl, cyano, amino, C 1  -C 4  -alkylamino, di-(C 1  -C 4  -alkyl)amino, C 1  -C 4  -alkanoyl amino groups and/or halogen atoms; a C 6  -C 10  -aroyl group which is unsubstituted or substituted by 1 to 3 C 1  -C 4  -alkyl, C 1  -C 4  -alkoxy, trifluoromethyl, nitro, hydroxyl, C 1  -C 4  -alkanoyl, carboxyl, C 1  -C 5  -alkoxy-carbonyl, N,N-di-(C 1  -C 4  -alkyl)-amido, cyano, di-(C.sub. 1 -C 4  -alkyl)-amino groups and/or halogen atoms; or a hetaroyl group having 5 to 6 ring members, which can contain 1 to 3 hetero atoms and may be benzofused; a C 3  -C 12  -cycloalkyl, C 1  -C 8  -acyl or (C 1  -C 5  -alkoxy)-carbonyl group or a C 6  -C 10  -aryl radical which is unsubstituted or monosubstituted, disubstituted or trisubstituted by halogen, C 1  -C 4  -alkyl, C 1  -C 4  -alkoxy, hydroxyl, trifluoromethyl, C 1  -C 4  -acyl, carboxyl, (C 1  -C 5  -alkoxy)-carbonyl, cyano, nitro, amino, C 1  -C 4  -alkylamino, di-C 1  -C 4  -alkylamino, arylamino or C 1  -C 4  -acylamino; or a 5-membered or 6-membered hetaryl radical which may be benzofused, contains 1 to 3 nitrogen atoms and may or may not contain an oxygen atom or sulfur atom, and p is 2 or 3, or   (e) a group of the formula V ##STR555## where R 12  and R 13  are each hydrogen, halogen, C 1  -C 4  -alkyl or C 1  -C 4  -alkoxy, and n is 1, 2 or 3.   
     
     
       2. 6-{p-[3-(4-Phenyl-1-piperazino)-propionylamino]-phenyl}-5-methyl-4,5-dihydro-3(2H)-pyridazinone. 
     
     
       3. 6-{p-[3-(4-Phyrid-2-yl-1-piperazino)-propionylamino]-phenyl}-5-methyl-4,5-dihydro-3(2H)-pyridazinone. 
     
     
       4. 6-{p-[3-(4-Benzyl-1-piperazino)propionylamino]-phenyl}-5-methyl-4,5-dihydro-3(2H)-pyridazinone. 
     
     
       5. 6-{p-[2-(5-Phenyl-1-piperidino)-acetylamino]-phenyl}-5-methyl-4,5-dihydro-3(2H)-pyridazinone. 
     
     
       6. 6-{p-[3-(4-Phenyl-1-piperidino)-propionylamino]-phenyl}-4,5-dihydropyridazinone. 
     
     
       7. 6-{p-[3-(4-Phenyl-1-piperidino)-propionylamino]-phenyl}-5-methyl-4,5-dihydropyridazinone. 
     
     
       8. .[.2-{p-[3-(4-Phenyl-1-piperidino)-propynylamino]-phenyl}-3,4-diazabicyclo[4.1.0]hept-2-en-5-one.]. .Iadd.2-{p-[3-(4-Phenyl-1-piperidino)-propionylamino]-phenyl}-3,4-diazabicyclo[4.1.0]hept-2-en-5-one..Iaddend. 
     
     
       9. 6-{p-[3-(4-Phenyl-1-(1,2,3,6-tetrahydropyridino)-propionylamino]-phenyl}-5-methyl-4,5-dihydro-3(2H)-pyridazinone. 
     
     
       10. 6-{p-[3-(4-Phenyl-1-piperidino)-propionylamino]-phenyl}-3(2H)-pyridazinone. 
     
     
       11. 6-{p-[3-(1,2,3,4-Tetrahydroisoquinolino)propionylamino]-phenyl}-5-methyl-4,5-dihydro-3(2H)-pyridazinone. 
     
     
       12. A .[.therapeutic.]. .Iadd.pharmaceutical .Iaddend.composition .Iadd.having thrombocyte aggregation-inhibiting activity .Iaddend.comprising .[.a pharmaceutical expedient and.]. an effective amount of a 6-(alkanoyl-aminoaryl)-3(2H)-pyridazinone derivative as claimed in claim .[.16.]. .Iadd.1 .Iaddend.as the active compound. 
     
     
       13. The method of treating disease caused by thrombocyte aggregation in a patient suffering therefrom which comprises administering an effective amount of a 6-(alkanoyl-aminoaryl)-3(2H)-pyridazinone derivative as claimed in claim .[.12.]. .Iadd.1.Iaddend..